14.66
+0.61(+4.34%)
Currency In USD
Address
No. 4 The Forum
Saint Helier, JE2 4UF
Jersey
Phone
44 15 3475 6700
Website
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
1488
First IPO Date
October 01, 2015
| Name | Title | Pay | Year Born |
| Ms. Ashley Cordova | Chief Executive Officer & Director | 1.09M | 1979 |
| Mr. Barak Ben-Arye | General Counsel | 796,075 | 1977 |
| Mr. Frank Leonard | Executive Vice President & President of Novocure Oncology | 819,784 | N/A |
| Dr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer | 1.05M | 1979 |
| Mr. William F. Doyle | Executive Chairman | 1.42M | 1962 |
| Mr. Michael Puri | Chief Human Resources Officer | 0 | 1969 |
| Dr. Nicolas Leupin M.B.A., M.D., Ph.D. | Chief Medical Officer | 0 | 1973 |
| Mr. Mukund Paravasthu | Chief Operating Officer | 0 | 1970 |
| Mr. Christoph Brackmann | Chief Financial Officer | 0 | 1974 |
| Ms. Ingrid Goldberg | Vice President of Investor Relations | 0 | N/A |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.